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Abstract
Due to expansion limits of the Absorb bioresorbable scaffold a meticulous implantation with correct sizing is required. We 
sought to investigate the clinical outcomes based on the sizing of the device related to the maximal lumen diameter measured 
by quantitative coronary angiography in Absorb BVS and Xience EES treated lesions in the AIDA trial. Sizing of Absorb 
bioresorbable vascular scaffold (BVS) and Xience everolimus eluting stent (EES) was graded according to the definitions 
of device non-oversize and device oversize on pre-procedural angiography. Lesion-oriented outcomes (LOCE) (device 
thrombosis, TLR and TVMI) that occurred during 2 years follow-up were related to device non-oversized or oversized sta-
tus. In the Absorb BVS group, LOCE occurred in 48 (7.4%) lesions in the oversized group and in 32 (8.2%) lesions in the 
non-oversized group (HR 0.91; 95% CI 0.58–1.42; p = 0.681), whereas TLR occurred in 34 (5.3%) lesions and in 23 lesions 
(5.9%), respectively (HR 0.89; 95% CI 0.52–1.51; p = 0.666). Definite scaffold thrombosis occurred in 11 (1.7%) device 
oversized treated lesions against 16 (4.1%) device non-oversized treated lesions (HR 0.41; 95% CI 0.19–0.89; p = 0.020). 
There were no differences in event rates between oversized and non-oversized groups in lesions treated with Xience EES. 
There was no significant difference in LOCE between oversized and non-oversized treated Absorb BVS and Xience EES 
treated lesions. Non-oversized Absorb BVS implantation was associated with a higher risk of scaffold thrombosis at complete 
2 years follow-up. The majority of very late scaffold thrombosis occurred in properly sized devices.
Keywords Bioresorbable scaffolds · Quantitative coronary angiography · Scaffold thrombosis · Target lesion 
revascularization · Device sizing
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Introduction
The early results of Absorb everolimus-eluting bioresorb-
able vascular scaffold (Absorb BVS) implantation in simple 
coronary lesions were promising [1–3]. Initial enthusiasm 
was hampered when large randomized trials with long-term 
follow-up reported higher rates of target lesion failure (TLF), 
and scaffold thrombosis in the Absorb BVS compared to 
Xience everolimus eluting stent (EES) [4–7].
The limitations of the device, as well as implantation 
techniques or strategies, have been proposed as possible 
causes of adverse events [8]. Proper sizing of the scaffold 
may be of great importance acutely after scaffold implanta-
tion. The limited ability to over-expand makes the Absorb 
BVS prone to scaffold disruption when an undersized device 
is implanted and aggressively post-dilated. Furthermore, 
implanting an oversized device has been shown to cause 
more edge dissections and peri-procedural myocardial 
infarctions [9–11].
Ishibashi et  al. demonstrated that implantation of an 
oversized Absorb BVS was associated with a higher risk 
of major adverse cardiac events (MACE) at 1 year [12]. 
Whereas, Katagiri et al. demonstrated that implantation of 
an undersized Absorb BVS was associated with a higher risk 
of MACE between 1 and 3 years [13]. This association was 
investigated in trials, which included only simple lesions and 
where quantitative assessment of the target vessel diameter 
by online quantitative coronary angiography (QCA) was 
required for enrollment in the trial [1–3, 14].
The Amsterdam Investigator-Initiated Absorb Strategy 
All-comers (AIDA) trial was an all-comers randomized 
controlled trial that analyzed Absorb BVS versus Xience 
EES in routine percutaneous coronary intervention (PCI). 
Although it demonstrated non-inferiority in the compos-
ite endpoint of target vessel failure (TVF) of Absorb BVS 
versus Xience EES at 2 years, Absorb BVS was associated 
with a higher risk of definite/probable device thrombosis 
[15]. In the current report we investigate whether proper 
sizing is a key factor leading to adverse events after device 
implantation and therefore we evaluated the relationship of 
maximum lumen diameter (Dmax) based device sizing on 
QCA, to lesion oriented outcomes in both the Absorb BVS 
and Xience EES arms of the AIDA trial.
Methods
Study design AIDA trial
The AIDA compared Absorb BVS (Abbott Vascular, Santa 
Clara, CA, USA) with Xience EES (Abbott Vascular, Santa 
Clara, CA, USA) in routine PCI. The study design [16], the 
preliminary safety report [6], and the 2-year results [15] have 
been published previously.
Briefly, between August 2013 and December 2015, 1845 
consecutive patients with coronary artery disease undergo-
ing PCI with one or more target lesions suitable for drug-
eluting stent implantation were included in AIDA. Key 
exclusion criteria were target lesions longer than 70 mm, 
a visually estimated reference vessel diameter of < 2.5 mm 
of > 4.0 mm, treatment of a true bifurcation lesion with a 
priori planned two device strategy, and treatment of in-stent 
restenosis. Patients were randomized after successful pre-
dilatation of the first lesion. Device sizing was based on 
visual assessment by the operator. Online QCA, or peripro-
cedural testing of cardiac biomarkers, were not mandatory. 
Device implantation strategy was planned according to the 
instructions for use of the implanted device.
Design of the current analysis
QCA analysis
The current analysis includes all study lesions treated with 
at least one study device of which baseline angiogram suited 
for offline QCA analysis was available. QCA assessment of 
device sizing relied on the angiographic diameter function 
curve of the pre-treatment vessel segment consisting of three 
non-ambiguous luminal dimensions; namely, the minimal 
lumen diameter (MLD) and the Dmax in the proximal seg-
ment (proximal Dmax) and in the distal segment of interest 
(distal Dmax) with respect to the MLD.
Pre- and post-procedural measurements were performed 
in either (1) multiple matched views or (2) a single matched 
view. If no matched views were available, measurements 
were done within the view with visually the highest steno-
sis grade. Proximal and distal Dmax were measured in (a) 
pre-procedural projection(s). In case of a total occlusion, 
the MLD was considered to be 0 mm; the proximal Dmax 
was measured in a pre-procedural projection; and the distal 
Dmax was considered similar to the proximal Dmax. Offline 
QCA analyses were initially performed on the post-proce-
dural angiograms within the Absorb BVS arm, and were 
performed by seven experienced readers [6]. We later added 
5 experienced readers to our academic Corelab, in order 
to complete pre-procedural measures on the Absorb BVS 
arm, and complete the pre-procedural and post-procedural 
measures within the Xience EES arm. All QCA analyses 
were performed using Cardiovascular Angiography Analy-
ses System [CAAS], version 5.11 (Pie Medical Imaging, 
Maastricht, the Netherlands). All QCA readers were blinded 
for clinical events, and were supervised by one cardiologist 
[YO], who is an expert in this field.
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Definitions
The study population in both arms was stratified by the dif-
ference between both the proximal and distal angiographic 
Dmax and the nominal diameter of the implanted device. 
The selection of device size was considered “oversized” 
when the proximal and distal Dmax of the treated lesion 
were smaller than the nominal size of the device. Lesions 
with either a proximal or a distal Dmax or both Dmax larger 
than the nominal size of the device constituted the “non-
oversized group”. When a patient received 2 or 3 overlap-
ping devices in a long lesion, the nominal size of the proxi-
mally implanted device was compared with the proximal 
Dmax, whereas the nominal size of the distally implanted 
device was compared with the distal Dmax. Devices were 
considered properly sized when the ratio of the proximal or 
distal Dmax minus the device diameter fell within the range 
of -0.5 to + 0.5 mm.
Lesion oriented endpoints
The lesion-oriented composite outcome (LOCE) of this 
analysis included definite device thrombosis, target lesion 
revascularization (TLR) and target vessel myocardial infarc-
tion (TVMI). All myocardial infarctions were defined by the 
Third Universal Myocardial Infarction definitions and other 
events were defined according to the Academic Research 
Consortium definitions. All reported events were adjudi-
cated by an independent Clinical Events Committee (Cardi-
alysis BV., Rotterdam, the Netherlands).
Statistical analysis
This report provides information on the lesion-oriented out-
comes subdivided by their device non-oversize or oversize 
status. All analyses were conducted using the per-protocol 
population. Descriptive statistics were used to present the 
data. Groups were compared using Chi square test and stu-
dent t-test. Kaplan–Meier method, log-rank test and Cox 
proportional hazards models were used for time-to-event 
analysis. Landmark analyses were performed at 31 days and 
365 days after index procedure. A 2-sided p value < 0.05 
was considered significant. The prognostic value for LOCE 
of device oversize was assessed in a univariate Cox pro-
portional-hazard analysis. In a multivariate Cox regression 
analysis we identified other statistically significant predic-
tors of LOCE. Next we performed a multivariate regression 
analysis for device oversize with adjustment for other statis-
tically significant predictors of LOCE.
The entry criterium for the multivariable analysis was 
set at p < 0.1. Device oversize was forced into the multivari-
ate model. All statistical tests were performed using SPSS 
software, version 23.0 (IBM SPSS Statistics, IBM Chicago, 
IL, USA).
Results
In the AIDA trial, 924 patients were randomized to treatment 
with Absorb BVS and 921 patients to treatment with Xience 
EES. A total of 2446 lesions were treated; 1237 lesions 
within the Absorb BVS arm and 1209 within the Xience 
EES arm. We excluded 89 lesions that did not receive any 
study device. Another 179 lesion were not analyzable, and 
were therefore excluded. Pre-procedural Dmax assessment 
was available in 2152 lesions (87.9%). The full study flow-
chart is shown in Fig. 1.
Baseline and angiographic characteristics of the over-
sized and non-oversized groups for both study devices 
are displayed in Tables 1 and 2. In 653 (62.0%) of Absorb 
BVS treated lesions, and 648 (59.0%) of Xience EES 
treated lesions an oversized device was implanted. Over-
sized devices were more frequently implanted in the left 
coronary artery, and in lesions with a TIMI flow of 0/1. In 
both study devices pre-procedural reference vessel diameter 
(RVD), both proximal and distal Dmax and minimal lumen 
diameter (MLD), were significantly smaller in the oversized 
groups compared with the non-oversized groups. Moreover, 
pre- and post-dilatation were less frequently performed in 
Fig. 1  The study flowchart. AIDA Amsterdam Investigator-Initiated 
Absorb Strategy All-comers, QCA quantitative coronary angiography, 
Dmax maximum diameter
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the Absorb BVS oversized group compared with the non-
oversized groups.
Lesion oriented outcomes
Lesion-oriented outcomes are shown in Table 3. LOCE 
occurred in 48 (7.4%) lesions in the Absorb BVS group over-
sized group and in 32 (8.2%) lesions in the non-oversized 
group (HR 0.91; 95%CI 0.58–1.42; p = 0.681).
LOCE occurred in 35 (5.5%) in the Xience EES group 
oversized group and in 22 (5.0%) lesions in the non-
oversized group (HR 1.11; 95% CI 0.65–1.89; p = 0.703). 
Kaplan–Meier curves for LOCE at 2 years after Absorb 
BVS or Xience EES implantation are shown in Figs. 2, 3, 
respectively.
Within the Absorb BVS arm TLR occurred in 34 (5.3%) 
lesions in the device oversized group and in 23 lesions 
(5.9%) in the device non-oversized group (HR 0.89; 95% 
CI 0.52–1.51; p = 0.666). TLR not caused by scaffold 
thrombosis occurred at higher, but non-significantly differ-
ent, rates in the device oversized group (HR 1.62; 95% CI 
0.75–3.49; p = 0.211). Definite scaffold thrombosis occurred 
in 11 (1.7%) device oversized treated lesions against 16 
(4.1%) device non-oversized treated lesions (HR 0.41; 95% 
CI 0.19–0.89; p = 0.020) (Fig. 3). Landmark analyses of 
definite scaffold thrombosis until 31-days, from 31 days to 
1 year, and from 1 to 2 years after scaffold implantation 
are shown in Fig. 4a–c. Definite scaffold thrombosis from 
1 to 2 years occurred less frequently in oversized Absorb 
BVS treated lesions (HR 0.25; 95% CI 0.07–0.98; p = 0.031). 
Figure 5a, b show explorative analysis of the distribution of 
proximal and distal Dmax minus the nominal device size 
in Absorb BVS treated lesions (A) and Xience EES treated 
lesions (B) with or without definite device thrombosis. The 
majority of very late scaffold thrombosis cases occurred 
in properly sized scaffolds that fell within the definitions 
of the Instructions for Use of the Absorb BVS and the 
Dmax assessment. Supplementary Figs. 1 and 2 show the 
Table 1  Shown are the clinical and angiographic characteristics of Absorb BVS treated lesions, stratified by oversized/non-oversized device
 Absorb BVS treated lesions
Device oversize
Device 
non-oversize
P Value
(n=653 ) (n= 401)
STEMI 142 (21.7%) 79 (19.7%) 0.188 
NSTEMI 26 (4.0%) 13 (3.2%) 0.750 
Lesion Locaon
 RCA 186 (28.5%) 157 (39.2%) <0.001 
 LAD 315 (48.2%) 140 (34.9%) <0.001 
 RCX 147 (22.5%) 99 (24.7%) 0.453 
 LM 2 (0.3%) 3 (0.7%) 0.375 
 Bypass gra 3 (0.5%) 2 (0.4%) 1.000 
TIMI 0 or 1 103 (15.8%) 40 (10.1%) 0.007 
Calcificaon 170 (26.0%) 115 (28.7%) 0.354 
Thrombus present 93 (14.2%) 52 (13.0%) 0.582 
Pre-procedural
Predilataon performed 633 (96.8%) 398 (99.5%) 0.002 
Reference Vessel Diameter 2.32 ±0.50 2.87 ±0.53 <0.001 
Proximal Dmax 2.53 ±0.50 3.29 ±0.59 <0.001 
Distal Dmax 2.43 ±0.50 3.07 ±0.60 <0.001 
Minimum Lumen Diameter 1.00 ±0.43 1.20 ±0.52 <0.001 
Diameter Stenosis 67.27 ±19.52 63.82 ±17.39 0.004 
Post-procedural
Post-dilataon performed 479 (73.4%) 330 (82.3%) 0.001 
Reference Vessel Diameter 2.50 ±0.46 2.78 ±0.74 <0.001 
Minimal lumen diameter 1.94 ±0.46 2.13 ±0.65 <0.001 
Diameter Stenosis (%) 22.95 ±10.46 23.13 ±10.36 0.800 
Plus-minus values are means ± SD
BVS bioresorbable vascular scaffold, (N)STEMI (non)ST-elevation myocardial infarction, RCA right coronary artery, LAD left anterior descend-
ing coronary artery, RCX ramus circumflex, TIMI thrombolysis in myocardial infarction, Dmax maximum diameter
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Table 2  Shown are the clinical 
and angiographic characteristics 
of Xience EES treated lesions, 
stratified by oversized/non-
oversized device
Plus-minus values are means ± SD
EES everolimus eluting stent, (N)STEMI (non)ST-elevation myocardial infarction, RCA right coronary 
artery, LAD left anterior descending coronary artery, RCX ramus circumflex, TIMI thrombolysis in myocar-
dial infarction, Dmax maximum diameter
Xience EES treated lesions Device oversize Device non-oversize P Value
(n = 648) (n = 450)
STEMI 151 (23.3%) 82 (18.2%) 0.010
NSTEMI 26 (4.0%) 22 (4.9%) 0.502
Lesion location
 RCA 178 (27.5%) 143 (31.8%) 0.138
 LAD 304 (46.9%) 172 (38.2%) 0.004
 RCX 161 (24.8%) 130 (28.9%) 0.144
 LM 2 (0.3%) 4 (0.9%) 0.234
Bypass graft 3 (0.5%) 1(0.2%) 0.648
TIMI 0 or 1 109 (16.8%) 36 (8.1%) 0.001
Calcification 170 (26.2%) 128 0.448
Thrombus present 102 (15.7%) 42 (71.6%) 0.002
Pre-procedural
 Predilatation performed 607 (93.7%) 406 (90.2%) 0.039
 Reference vessel diameter 2.31 ± 0.57 2.79 ± 0.59 < 0.001
 Proximal Dmax 2.58 ± 0.50 3.24 ± 0.65 < 0.001
 Distal Dmax 2.50 ± 0.49 3.04 ± 0.65 < 0.001
 Minimum lumen diameter 0.94 ± 0.37 1.09 ± 0.46 < 0.001
 Diameter stenosis 68.77 ± 18.67 66.06 ± 16.85 < 0.001
Post-procedural
 Post-dilatation performed 295 (45.5%) 243(54.0%) 0.008
 Reference vessel diameter 2.54 ± 0.50 2.76 ± 0.57 < 0.001
 Minimal lumen diameter 1.88 ± 0.48 2.06 ± 0.51 < 0.001
 Diameter stenosis (%) 26.23 ± 11.68 25.30 ± 11.11 0.189
Table 3  Shown are the lesion oriented outcomes at 2 years of Absorb BVS and Xience EES treated lesions
Lesion-oriented Outcomes Device  oversize 
Device  
non-oversize Hazard Rao (95% CI) P-value Pinteracon
a
Adjusted  
mulvariate modelb
Hazard rao (95% CI) 
P-value 
Absorb BVS N=653 N=401 
Lesion Oriented Composite endpoint 7.4% (48)  8.2% (32) 0.91 (0.58 -1.42) 0.681 0.579 0.91 (0.57 – 1.46) 0.703 
Target Lesion Revascularizaon 5.3% (34) 5.9% (23) 0.89 (0.52 – 1.51) 0.666 0.466 0.92 (0.53 – 1.60) 0.758 
Target Lesion Revascularizaon not 
caused by scaffold thrombosis 
3.8% (24) 2.3% (9) 1.62 (0.75 – 3.49) 0.211 0.658 1.88 (0.84 – 4.20) 0.123 
Definite Scaffold Thrombosis 1.7% (11) 4.1% (16) 0.41 (0.19 – 0.89) 0.020 0.350 0.33 (0.14 – 0.78) 0.012 
Target Vessel Myocardial Infarcon 4.0% (26) 6.9% (27) 0.58 (0.34 – 1.00) 0.046 0.245 0.53 (0.30 – 0.95) 0.034 
Xience EES N=648 N=450  
Lesion Oriented Composite endpoint 5.5% (35) 5.0% (22) 1.11 (0.65 – 1.89) 0.703 - 1.03 (0.60 – 1.76) 0.915 
Target Lesion Revascularizaon  4.1% (26)  3.4% (15) 1.21 (0.64 – 2.29) 0.553 - 1.11 (0.59 – 2.11) 0.746 
Target Lesion Revascularizaon not 
caused by scaffold thrombosis 
3.8% (24) 2.9% (13) 1.29 (0.66 – 2.54) 0.458 - 1.19 (0.60 – 2.35) 0.615 
Definite Stent Thrombosis 0.5% (3)  0.5% (2) 1.05 (0.18 – 6.25) 0.962 - 0.84 (0.14 – 5.12) 0.852 
Target Vessel Myocardial Infarcon 2.5% (16) 2.5% (11) 1.01 (0.47 – 2.19) 0.971 - 0.99 (0.46 – 2.13) 0.976 
BVS bioresorbable vascular scaffold, EES everolimus eluting stent, CI confidence interval
a Interaction for device oversize and device modality
b Adjusted for age, male sex and Syntax score for Absorb BVS, and adjusted for hypertension, hypercholesterolemia, any diabetes mellitus, and 
moderate to severe calcification for Xience EES
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ROC curves of the relative difference between the Dmax 
and the device diameter and LOCE (1) and definite device 
thrombosis (2) at 2 years after Absorb BVS or Xience EES 
implantation.
The predictors of LOCE at 2 years after Absorb BVS 
or Xience EES implantation are shown in supplementary 
table 1 and 2, respectively.
Discussion
The main findings of this AIDA sub study are:
1. We found no difference in Lesion-oriented Composite 
Endpoint between oversized and non-oversized Absorb 
BVS treated lesions.
2. Definite Scaffold Thrombosis and Target Vessel Myo-
cardial Infarction occurred more frequently in non-over-
sized Absorb BVS treated lesions, especially between 1 
and 2 year follow-up.
3. Most cases of definite scaffold thrombosis occurred in 
properly sized Absorb BVS according to the Instructions 
for Use of Absorb BVS and Dmax assessment.
4. We found no difference in lesion-oriented outcomes 
between oversized and non-oversized Xience EES 
treated lesions.
Scaffold thrombosis is an unpredictable severe complica-
tion, which usually results in myocardial infarction, or even 
cardiac death. Several studies have investigated whether 
Absorb BVS optimized implantation techniques are able to 
resolve the scaffold thrombosis issue. The results of these 
studies are, however, equivocal. Correct scaffold sizing 
remains a challenge in routine PCI because appropriate 
device selection relies on the device to coronary diameter 
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Fig. 2  Shown are the event rates of the lesion oriented composite endpoint in oversized or non-oversized Absorb BVS (a) and Xience EES (b) 
treated lesions. BVS bioresorbable vascular scaffold, EES everolimus eluting stent, CI confidence interval, no. number
Fig. 3  Shown are the event rates of definite scaffold thrombosis in 
oversized or non-oversized Absorb BVS treated lesions. BVS biore-
sorbable vascular scaffold, CI confidence interval, no. number
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ratio and its potential mismatch [12, 17]. Correct scaffold 
sizing is particularly difficult in long tapered lesions. It is 
known that the avoidance of a scaffold to coronary diameter 
mismatch is associated with less frequent ischemia driven 
TLR, whereas scaffold oversizing may be associated with 
higher rates of MACE at 1 year follow-up [12]. Whether 
this theory also applies to metallic stents remains unknown.
In the current analysis we investigated the relationship 
between Dmax based device sizing and lesion-oriented out-
comes in both the Absorb BVS as the Xience EES treated 
arm of the AIDA trial. Dmax based device sizing is a lesion 
specific characteristic, and therefore we present specific 
lesion-oriented outcomes. In contrast with the findings of 
Ishibashi et al, our analysis showed that oversized Absorb 
BVS were not associated with higher rates of lesion ori-
ented events. This may be due to the difference in MI defi-
nition in the two studies, namely in AIDA trial there was 
no routine post-procedure marker measurement and only 
clinically significant post-procedural myocardial infarc-
tions were captured. However, from 1 to 2 year follow-up, 
similarly to Katagiri et al. we found significant increase in 
the rates of device thrombosis in non-oversized Absorb BVS 
Fig. 4  Landmark analysis of definite scaffold thrombosis at 31 days (a), 31 to 365 days (b) and 1–2 years (c). BVS bioresorbable vascular scaf-
fold, CI confidence interval, no. number
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treated lesions. Furthermore, most cases of very late scaffold 
thrombosis occurred in properly sized devices [13]. This 
later finding may implicate the complex interaction between 
vessel wall and the device resorption and dismantling pro-
cess rather that any initial procedural technique as a major 
factor in very late stent thrombosis cases.
Our study is the first to investigate the effect of Dmax 
based device sizing in Xience EES treated lesions. We found 
no difference in event rates between oversized and non-over-
sized Xience EES treated lesions. Definite stent thrombosis 
is unpredictable and does not depend on the Xience EES 
/ coronary artery diameter mismatch. Moreover, all three 
acute stent thrombosis occurred in properly sized devices, 
in patients taking dual antiplatelet therapy, suggesting that 
other factors than implantation technique play a role in the 
occurrence. These results can potentially be attributed to the 
better device characteristics of the Xience EES such as thin-
ner struts, better expansion limits, higher tensile and radial 
strength as compared to Absorb BVS.
The insights of this AIDA sub-study can be useful for 
the development of the next generation coronary bioresorb-
able scaffolds, with wider expansion limits and better tensile 
Fig. 5  Shown is the distribution 
of proximal and distal Dmax 
minus the nominal device size 
in Absorb BVS (a) or Xience 
EES (b) treated lesions with 
or without definite device 
thrombosis. BVS bioresorbable 
vascular scaffold, Dmax maxi-
mum diameter, EES everolimus 
eluting stent
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and radial strength, potentially resolving the scaffold sizing 
issues and difficulties. In addition, QCA or intravascular 
imaging should be strongly considered in forthcoming trials 
of new generation bioresorbable coronary scaffolds.
Limitations
The current analysis has several limitations. First, in AIDA, 
device sizing based on online QCA was not mandatory, and 
therefore incorrect device sizing is likely to have occurred 
more frequently. Second, routine intravascular imaging has 
not been performed and therefore the study does not provide 
mechanistic insights in the occurrence of events due to a 
device / artery diameter mismatch. Third, the role of lesion 
morphology and typology stratification as a prognostic fac-
ture for device failure has not been analyzed in the current 
explorative analysis. The gold standard for lesion morphol-
ogy and typology stratification is intracoronary imaging. The 
AIDA population reflects routine PCI, and since intracoro-
nary imaging is not a part of routine PCI (used in less than 
10% of the cases), it was not possible to explore the exact 
role of these factors in this study. Fourth, as with all post-hoc 
analysis, this AIDA sub-study is subject to under powering.
Conclusions
In this AIDA trial sub-study, we found no significant differ-
ence in LOCE between oversized and non-oversized treated 
Absorb BVS and Xience EES treated lesions. However, non-
oversized Absorb BVS implantation was associated with a 
higher risk of scaffold thrombosis at complete 2 years fol-
low-up, in particular between 1 and 2 years follow-up.
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